X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Alaya.bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 20, 2023
Details:
TNP – composed of proprietary polymer capsule ‘OM-PBAE’ polymers (oligopeptide end-modified poly β-amino-ester polymers) directed to specific cells through targeting agents attached capsule (an aptamer-based targeting moiety) and celtic (Lentivirus Based CAR T-cell Therapy).
Lead Product(s): Lentivirus Based CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Celtic
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer® reagents previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers.
Lead Product(s): AntigenxCD3 Bispecific Aptamers
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: SomaLogic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2021
Details:
The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development for the treatment of CLTI.
Lead Product(s): Rexmyelocel-T
Therapeutic Area: Cardiology/Vascular Diseases Product Name: REX-001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $55.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
